SI3417875T1 - Formulacija imunoglobulina in metode za njegovo pripravo - Google Patents

Formulacija imunoglobulina in metode za njegovo pripravo

Info

Publication number
SI3417875T1
SI3417875T1 SI200432502T SI200432502T SI3417875T1 SI 3417875 T1 SI3417875 T1 SI 3417875T1 SI 200432502 T SI200432502 T SI 200432502T SI 200432502 T SI200432502 T SI 200432502T SI 3417875 T1 SI3417875 T1 SI 3417875T1
Authority
SI
Slovenia
Prior art keywords
preparation
immunoglobulin formulation
immunoglobulin
formulation
Prior art date
Application number
SI200432502T
Other languages
English (en)
Slovenian (sl)
Inventor
David J. Burke
Shaun E. Buckley
Sherwood Russ Lehrman
Barbara Horsey O'connor
James Callaway
Christopher Phillips
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32869424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3417875(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of SI3417875T1 publication Critical patent/SI3417875T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200432502T 2003-02-10 2004-02-09 Formulacija imunoglobulina in metode za njegovo pripravo SI3417875T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44581803P 2003-02-10 2003-02-10
EP18174115.8A EP3417875B1 (en) 2003-02-10 2004-02-09 Immunoglobulin formulation and method of preparation thereof

Publications (1)

Publication Number Publication Date
SI3417875T1 true SI3417875T1 (sl) 2021-01-29

Family

ID=32869424

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200432502T SI3417875T1 (sl) 2003-02-10 2004-02-09 Formulacija imunoglobulina in metode za njegovo pripravo
SI200432441T SI2236154T1 (en) 2003-02-10 2004-02-09 THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200432441T SI2236154T1 (en) 2003-02-10 2004-02-09 THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION

Country Status (28)

Country Link
US (7) US20050053598A1 (enExample)
EP (4) EP1592440A4 (enExample)
JP (3) JP4728948B2 (enExample)
KR (1) KR20050110628A (enExample)
CN (2) CN103040732B (enExample)
AR (1) AR043144A1 (enExample)
AU (2) AU2004210679A1 (enExample)
CA (1) CA2515444C (enExample)
CL (1) CL2004000224A1 (enExample)
CY (2) CY1120574T1 (enExample)
DK (2) DK2236154T3 (enExample)
ES (1) ES2819011T3 (enExample)
HU (1) HUE051878T2 (enExample)
IL (1) IL170008A (enExample)
MX (1) MXPA05008409A (enExample)
MY (1) MY162623A (enExample)
NO (1) NO346070B1 (enExample)
PE (1) PE20050190A1 (enExample)
PT (2) PT3417875T (enExample)
RU (1) RU2358763C2 (enExample)
SI (2) SI3417875T1 (enExample)
SK (1) SK50672005A3 (enExample)
TR (1) TR201808801T4 (enExample)
TW (1) TWI367766B (enExample)
UA (1) UA82685C2 (enExample)
UY (1) UY28184A1 (enExample)
WO (1) WO2004071439A2 (enExample)
ZA (1) ZA200506159B (enExample)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535320A (en) 2002-02-25 2008-05-30 Elan Pharm Inc Administration of agents that bind to an alpha-4 integrin for the treatment of inflammation
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
CA2496834C (en) * 2002-09-06 2014-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
SI3417875T1 (sl) * 2003-02-10 2021-01-29 Biogen Ma Inc. Formulacija imunoglobulina in metode za njegovo pripravo
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
TR201816556T4 (tr) * 2004-04-02 2018-11-21 Swedish Orphan Biovitrum Ab Publ Il-1ra agregasyonunun azaltilmasina yöneli̇k yöntemler
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN103169965A (zh) * 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
TW200719913A (en) * 2005-03-08 2007-06-01 Pharmacia & Upjohn Co Llc Anti-madcam antibody compositions
US8858935B2 (en) * 2005-05-19 2014-10-14 Amgen Inc. Compositions and methods for increasing the stability of antibodies
CA2625815A1 (en) * 2005-09-12 2007-03-22 Novimmune S.A. Anti-cd3 antibody formulations
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
DK2548577T3 (en) 2005-12-29 2017-03-13 Janssen Biotech Inc HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2066350A4 (en) * 2006-09-25 2010-04-07 Medimmune Llc STABILIZED ANTIBODY FORMULATIONS AND THEIR USES
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
ES2925992T3 (es) 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
TW200837080A (en) * 2007-01-09 2008-09-16 Wyeth Corp Anti-IL-13 antibody formulations and uses thereof
JP5303792B2 (ja) * 2007-02-12 2013-10-02 ボウジベル，ラサアド 保存料を含まないスクラロース無菌溶液
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20080311119A1 (en) * 2007-06-14 2008-12-18 Biogen Idec Ma Inc. Antibody formulations
WO2009003010A2 (en) * 2007-06-25 2008-12-31 Becton, Dickinson And Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
ES2543735T3 (es) * 2007-10-22 2015-08-21 Becton Dickinson And Company Artículos médicos revestidos con organopolisiloxano que contienen una disolución de proteína y un tensioactivo no iónico
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
PT2271382E (pt) 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
CA2734919C (en) 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
WO2010077045A2 (en) * 2008-12-29 2010-07-08 Samyang Corporation Pharmaceutical composition of lyophilized formulation and preparation method of the same
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
AU2010236257A1 (en) * 2009-04-17 2011-11-03 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
KR101441768B1 (ko) * 2009-09-17 2014-09-17 박스터 헬쓰케어 에스에이 히알루로니다아제 및 면역글로불린의 안정한 복합제제, 및 그 사용방법
PL2485761T3 (pl) * 2009-10-09 2019-10-31 Armagen Inc Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CN107693791B (zh) * 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
ME02793B (me) 2010-04-16 2018-01-20 Biogen Ma Inc Anti-vla-4 antitijela
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
US9095567B2 (en) 2010-06-04 2015-08-04 Wyeth Llc Vaccine formulations
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CA2810734A1 (en) 2010-09-17 2012-03-22 Baxter International Inc. Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
HRP20241666T1 (hr) 2010-10-25 2025-02-14 Biogen Ma Inc. Metode za određivanje razlika u alfa-4 integrinskoj aktivnosti pomoću korelacijskih razlika u razinama svcam i/ili smadcam
MX344727B (es) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP2691112B1 (en) 2011-03-31 2018-05-23 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
KR20140033171A (ko) * 2011-05-26 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 비활성화된 뎅기 바이러스 백신
CA2840711C (en) * 2011-07-01 2023-10-17 Biogen Idec Ma Inc. Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
CN104169299B (zh) * 2012-01-23 2018-06-05 瑞泽恩制药公司 含抗Ang-2 抗体的稳定化制剂
EP3431104A1 (en) * 2012-03-26 2019-01-23 Sanofi Stable igg4 binding agent formulations
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
PT3071237T (pt) 2013-11-21 2024-08-26 Genmab As Formulação liofilizada de conjugados anticorpo-fármaco
US9932591B2 (en) 2013-12-18 2018-04-03 University Of Delaware Reduction of lipase activity in product formulations
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
TWI752912B (zh) * 2015-07-17 2022-01-21 美商寇西勒斯生物科技股份有限公司 那他珠單抗的穩定水性調配物
US10484453B2 (en) * 2015-07-29 2019-11-19 Xerox Corporation System and method for printing documents using print hardware and automatic context inference
NZ744185A (en) 2015-12-30 2025-09-26 Kodiak Sciences Inc Antibodies and conjugates thereof
ES2983242T3 (es) 2016-01-13 2024-10-22 Genmab As Formulación para anticuerpo y conjugado de fármaco del mismo
US10914720B2 (en) 2016-02-10 2021-02-09 Becton Dickinson France Method to evaluate the stability of a protein-based formulation
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
KR102686858B1 (ko) 2017-12-06 2024-07-19 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
WO2019110823A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US20190269757A1 (en) 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019173767A1 (en) 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CN112243379A (zh) * 2018-04-10 2021-01-19 雷迪博士实验室有限公司 稳定的抗体制剂
EP3773696A4 (en) 2018-04-10 2021-12-29 Dr. Reddy's Laboratories Ltd. Stable formulations of therapeutic antibody
EP3773694A4 (en) * 2018-04-10 2021-12-29 Dr. Reddy's Laboratories Ltd. Antibody formulation
UA130009C2 (uk) 2018-05-07 2025-10-15 Генмаб А/С Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу
EP3800999A4 (en) 2018-06-04 2022-06-01 Biogen MA Inc. ANTI-VLA-4 ANTIBODY WITH REDUCED EFFECTIVE FUNCTION
BR112020025001A2 (pt) 2018-06-08 2021-03-23 Argenx Bvba composições e métodos para o tratamento da trombocitopenia imune
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
KR20210024082A (ko) * 2018-06-25 2021-03-04 제이씨알 파마 가부시키가이샤 단백질 함유 수성 액제
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
CN113453708B (zh) 2018-12-19 2025-02-21 默沙东有限责任公司 包含肺炎链球菌多糖-蛋白缀合物的组合物及其使用方法
EP3903815A4 (en) 2018-12-24 2022-09-28 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
CA3138072A1 (en) * 2019-06-07 2020-12-10 Argenx Bvba Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
KR20220019756A (ko) * 2019-06-11 2022-02-17 마크로제닉스, 인크. 이중특이적 디아바디의 제약학적 제제 및 그것의 용도
EP4007605A4 (en) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021124793A1 (ja) * 2019-12-16 2021-06-24 ニプロ株式会社 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
EP4454711A3 (en) 2020-01-08 2025-01-08 argenx BV Methods for treating pemphigus disorders
IL294461A (en) * 2020-01-13 2022-09-01 Aptevo Res & Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
AU2021213153A1 (en) * 2020-01-29 2022-08-04 Merck Sharp & Dohme Llc Methods of separating host cell lipases from an anti-LAG3 antibody production
JP2023528265A (ja) 2020-05-21 2023-07-04 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３に対する抗体及びｔｎｆアルファに対する抗体の組み合わせ療法を用いた炎症性腸疾患の治療方法
EP4243859A4 (en) * 2020-11-12 2024-10-16 Dr. Reddy's Laboratories Ltd. STABLE AQUEOUS FORMULATION WITH HIGH CONCENTRATION OF ANTI-INTEGRIN ANTIBODY
AU2023236910A1 (en) 2022-03-14 2024-08-01 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
IL317653A (en) 2022-06-15 2025-02-01 argenx BV FCRN/HSA binding molecules and methods of using them
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2560155C2 (de) * 1974-03-08 1984-04-26 Teijin Ltd., Osaka Humanimmunglobulin-Derivat
US4362661A (en) * 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
DK2275119T3 (da) * 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
DE19912637A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DK2168984T3 (da) 1999-03-25 2012-12-10 Abbott Gmbh & Co Kg Humane antistoffer, som binder humant IL-12, og fremgangsmåder til pro-duktion heraf
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
IL151150A0 (en) * 2001-01-31 2003-04-10 Roehm Gmbh Multiparticulate drug form comprising at least two differently coated pellet forms
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
NZ535320A (en) * 2002-02-25 2008-05-30 Elan Pharm Inc Administration of agents that bind to an alpha-4 integrin for the treatment of inflammation
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
SI3417875T1 (sl) * 2003-02-10 2021-01-29 Biogen Ma Inc. Formulacija imunoglobulina in metode za njegovo pripravo
US7807187B2 (en) 2003-05-13 2010-10-05 The University Of Massachusetts Endogenous adjuvant molecules and uses thereof
CA2555365A1 (en) 2004-02-06 2005-08-25 Elan Pharmaceuticals, Inc. Methods and compositions for treating tumors and metastatic disease
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
US20080311119A1 (en) 2007-06-14 2008-12-18 Biogen Idec Ma Inc. Antibody formulations

Also Published As

Publication number Publication date
TR201808801T4 (tr) 2018-07-23
IL170008A (en) 2015-05-31
TWI367766B (en) 2012-07-11
UY28184A1 (es) 2004-09-30
CN103040732A (zh) 2013-04-17
JP2014028831A (ja) 2014-02-13
US8900577B2 (en) 2014-12-02
AR043144A1 (es) 2005-07-20
CN1771053B (zh) 2012-10-03
RU2005128280A (ru) 2006-06-10
NO20054164L (no) 2005-09-07
EP3417875B1 (en) 2020-06-17
CY1123667T1 (el) 2022-03-24
DK2236154T3 (en) 2018-06-25
UA82685C2 (uk) 2008-05-12
AU2010202254A1 (en) 2010-06-24
US20180194843A1 (en) 2018-07-12
JP2011088913A (ja) 2011-05-06
US20130071386A1 (en) 2013-03-21
CY1120574T1 (el) 2019-07-10
CA2515444C (en) 2014-04-01
HK1182021A1 (en) 2013-11-22
US20100021461A1 (en) 2010-01-28
DK3417875T3 (da) 2020-08-31
CA2515444A1 (en) 2004-08-26
PT2236154T (pt) 2018-06-26
RU2358763C2 (ru) 2009-06-20
SK50672005A3 (sk) 2006-03-02
MY162623A (en) 2017-06-30
EP1592440A4 (en) 2007-07-11
EP1592440A2 (en) 2005-11-09
PE20050190A1 (es) 2005-03-21
PT3417875T (pt) 2020-08-24
US20050053598A1 (en) 2005-03-10
EP3417875A1 (en) 2018-12-26
HUE051878T2 (hu) 2021-03-29
JP2006517233A (ja) 2006-07-20
US10954303B2 (en) 2021-03-23
EP2236154A1 (en) 2010-10-06
US20210292419A1 (en) 2021-09-23
TW200505478A (en) 2005-02-16
JP4728948B2 (ja) 2011-07-20
US20120328614A1 (en) 2012-12-27
WO2004071439A3 (en) 2005-07-07
CL2004000224A1 (es) 2005-01-21
ZA200506159B (en) 2006-10-25
US8815236B2 (en) 2014-08-26
US8349321B2 (en) 2013-01-08
AU2004210679A1 (en) 2004-08-26
MXPA05008409A (es) 2005-10-05
EP2236154B1 (en) 2018-05-30
EP3777880A1 (en) 2021-02-17
CN1771053A (zh) 2006-05-10
CN103040732B (zh) 2015-04-01
ES2819011T3 (es) 2021-04-14
SI2236154T1 (en) 2018-08-31
WO2004071439A2 (en) 2004-08-26
US20150044206A1 (en) 2015-02-12
KR20050110628A (ko) 2005-11-23
NO346070B1 (no) 2022-01-31
AU2010202254B2 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
TWI367766B (en) Immunoglobulin formulation and method of preparation thereof
HUE038498T2 (hu) Immunglobulin készítmény és elõállítási módszere
IL172689A0 (en) Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
SI1698640T1 (sl) Postopek za stabiliziranje protitelesa in stabiliziran pripravek protitelesa tipa raztopina
EP1648316A4 (en) VERTEBRAL RETENTION AND CLEARANCE DEVICE AND METHOD OF USE
IL201409A0 (en) Cd40 antibody formulation and methods
IL169648A0 (en) Novel structures and method of preparation
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
ZA200506790B (en) Arylvinylazacycloalkane compounds and method of preparation and use thereof
AU2002326751A1 (en) Immunoglobulin e vaccines and methods of use thereof
SG115668A1 (en) Projection system and method of use thereof
IL175657A0 (en) Derivatives of dihydronepetalactone and method for preparation
AU2002246950A1 (en) Hydrocapsules and method of preparation
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
EP1633850A4 (en) OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
AU2003282593A8 (en) Polyphenolamine composition and method of use
EP1710584A4 (en) METHOD OF MEASURING LIPOARABINOMANANE AND ITS USE
AU2003238229A1 (en) Magnetorheological fluids and related method of preparation
GB0217372D0 (en) Psoriasis formulation and method of preparation
GB0223719D0 (en) Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
EP1616020A4 (en) ANTI-CR1 ANTIBODIES WITH REDUCED IMMUNOGENICITY AND COMPOSITIONS AND TREATMENT METHODS BASED ON THEM
GB0217269D0 (en) Psoriasis formulation and method of preparation
GB2408013B (en) Building components and method of manufacture
PL356684A1 (en) Method of receiving dietetic-therapeutic preparations and their application
AU2003906485A0 (en) Method and device for preparation of interconnecting material